Loading...
 
Toggle Health Problems and D

Vitamin D Receptor and Cancer


Vitamin D Receptor and Cancers in VitaminDWiki

Items in both categories Vitamin D Receptor and Cancer - Breast:

Items in both categories Vitamin D Receptor and Cancer - Colon:

Items in both categories Vitamin D Receptor and Cancer

Items in both categories Vitamin D Receptor and Cancer - other:

Items in both categories Vitamin D Receptor and Cancer - Skin:

Items in both categories Vitamin D Receptor and Cancer - Prostate:

Items in both categories Vitamin D Receptor and Cancer - Ovarian:

Vitamin D Receptor is associated in over 40 autoimmune studies

Vitamin D Receptor activation can be increased by any of: Resveratrol,  Omega-3,  MagnesiumZinc,   Quercetin,   non-daily Vit D,  Curcumin, intense exercise,   Ginger,   Essential oils, etc  Note: The founder of VitaminDWiki uses 10 of the 12 known VDR activators


Vitamin D Receptor Polymorphisms and Cancer (Book Chapter) - 2020

Sunlight, Vitamin D and Skin Cancer pp 53-114
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1268)
Patrizia GnagnarellaSara RaimondiValentina AristarcoHarriet Ann JohanssonFederica BellerbaFederica CorsoSara Gandini

Book: Sunlight, UV, Vitamin D and Receptor, Skin and other Cancers - Dec 2020 entire book is free

Increasing scientific evidence supports the link between vitamin D and cancer risk. The active metabolite 1,25(OH)2D exerts its activity by binding to the vitamin D receptor (VDR), an intracellular receptor that mediates transcriptional activation and repression of target genes. The binding of 1,25(OH)2D to VDR is able to regulate hundreds of different genes. VDR is active in virtually all tissues including the colon, breast, lung, ovary, bone, kidney, parathyroid gland, pancreatic b-cells, monocytes, T lymphocytes, melanocytes, keratinocytes, and also cancer cells.

The relevance of VDR gene restriction fragment length polymorphisms for various types of cancer has been investigated by a great number of studies.

We have carried out a systematic review of the literature to analyze the relevance of more VDR polymorphisms (Fok1, Bsm1, Taq1, Apa1, and Cdx2) for individual malignancies considering ethnicity as a key factor for heterogeneity.

Up to December 2018, we identified 176 independent studies with data to assess the risk of breast, prostate, colorectal, skin (melanoma and non-melanoma skin cancer), lung, ovarian, kidney, bladder, gallbladder, esophageal, thyroid, head and neck, liver and pancreatic cancer, oral squamous cell carcinoma, non-Hodgkin lymphoma, multiple myeloma and sarcoma.

Significant associations with VDR polymorphisms have been reported for prostate (Fok1, Bsm1, Taq1, Apa1, Cdx2), breast (Fok1, Bsm1, Taq1, Apa1, CdX2), colorectal (Fok1, Bsm1, Taq1, Apa1), and skin cancer (Fok1, Bsm1, Taq1). Very few studies reported risk estimates for the other cancer sites.

Conflicting data have been reported for most malignancies, and at present, it is still not possible to make any definitive statements about the importance of the VDR genotype for cancer risk. It seems probable that other factors such as ethnicity, phenotype, 25(OH)D plasma levels, and UV radiation exposure play a role as confounding factors and introduce heterogeneity.

To conclude, there is some indication that VDR polymorphisms may modulate the risk of some cancer sites and in future studies VDR genetic variation should be integrated also with assessment of vitamin D status and stratified by ethnicity.


Created by admin. Last Modification: Sunday April 18, 2021 22:22:55 GMT-0000 by admin. (Version 3)
Vitamin D Receptor and Cancer        
501 visitors, last modified 18 Apr, 2021,
Printer Friendly PDF this page! Follow this page for updates
See any problem with this page? Report it (FINALLY WORKS)